Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health

Neri, Manuela; Pilloni, Monica; Paoletti, Anna Maria; Melis, Gian Benedetto; Piras, Bruno; Ajossa, Silvia; Marotto, Maria Francesca; Corda, Valentina; Ronchi, Alessandro Nobili Luigina; Giancane, Elena; Vallerino, Valerio; Saba, Alessandra; Zedda, Pierina; Orani, Maria Paola; Cappai, Riccardo; Coghe, Ferdinando; Mais, Valerio

doi:10.1080/09513590.2019.1576618

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many previous studies have proven the role of ulipristal acetate (UPA) in decreasing the size of myoma as well as associated symptoms like heavy menstrual bleeding [11][12][13]. Previous studies have also demonstrated better bleeding control, shorter time to amenorrhoea, and minimal effect on bone mineral density with UPA use compared to GnRH analogue [11,14]. However, previous trial included mostly Caucasian women who were racially different from the Indian population.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of two repeated cycles of ulipristal acetate in the management of symptomatic uterine fibroid among Indian women

Jha

Ahmed

Sinha

2021

View full text Add to dashboard Cite

Introduction: To evaluate the safety and efficacy along with the impact on uterine and fibroid vascular indices of 2 repeat 12-week courses of ulipristal acetate (UPA) among Indian women.Material and methods: Ninety-four premenopausal women aged 18-45 years with at least 1 symptomatic fibroid of size ranging from 1 cm to 10 cm were included in the study. All participants received 2 courses of 5 mg of UPA orally for 12 weeks starting from the 5th day of their menstrual cycle with a 2-menstrual-cycle break in between. The efficacy was measured in terms of time to amenorrhoea, percentage of women who achieved amenorrhoea for the last 35 consecutive days, reduction in uterine and fibroid volume, as well as its vascularity at the end of the first and second treatment cycle.Results: Eighty-six women completed the first treatment cycle whereas only 65 women completed the second treatment course. Seventy-nine per cent of women achieved amenorrhoea for 35 consecutive days during the first treatment cycle. Median time to amenorrhoea was 7 days and 5 days during the first and second treatment cycle, respectively. Percentage reduction of the mean fibroid volume was 32% and 52% after the first and second treatment cycle, respectively. We observed an increase in fibroid vascular indices (pulsatility index and resistive index) suggesting reduction in fibroid vascularity. Serum oestradiol remained at mid-follicular phase. No serious drug emergent side effect was noted.Conclusions: Two interrupted repeat course of 5mg UPA is well tolerated efficient and safe in symptomatic fibroid among Indian women.

show abstract